April 15th, 2010 New developments in castration resistant prostate cancer – MDV3100
Last night I received an alert from Medivation announcing that an article would be published in today’s online The Lancet regarding their prostate cancer agent, MDV3100. Sure enough, here’s the article : Although the trial is an early phase I/II study, encouraging antitumour effects were reported in 140 men, of whom 65 were chemotherapy naïve. Time to disease progression (TTP) was 47 weeks, which is decent considering the men in the study were all castration resistant and likely had advanced disease.
